Distribution of Inflammatory Infiltrate in Feline Mammary Lesions: Relationship With Clinicopathological Features.
feline mammary tumours
inflammation
mammary gland microenvironment
tertiary lymphoid structures
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
11 Jun 2024
11 Jun 2024
Historique:
revised:
25
03
2024
received:
30
01
2024
accepted:
21
05
2024
medline:
12
6
2024
pubmed:
12
6
2024
entrez:
12
6
2024
Statut:
aheadofprint
Résumé
Inflammation is a frequent finding in feline mammary neoplasms. Recent research suggests that the presence and location of tumour-associated immune cells might play a significant role in the clinical outcome of feline mammary carcinomas. The present study aimed to characterise the overall inflammatory infiltrates in healthy, hyperplastic/dysplastic, benign and malignant lesions of the feline mammary gland, and to evaluate its association with clinicopathological features. Perilesional and intralesional inflammatory foci were evaluated in 307 lesions from 185 queens, and categorised according to its distribution and intensity. The presence, location and density of tertiary lymphoid structures were also assessed. A control group included 24 queens without mammary changes. The presence of intralesional and perilesional inflammatory infiltrate was observed in a majority of the lesions (80.8% and 90.2%, respectively), but differed according to the type of mammary lesion, being more remarkable in malignant neoplasms. Only scarce individual cells were observed in 28.1% of the normal mammary glands. Data analysis revealed statistically significant associations (p < 0.05) between the presence of a more prominent intralesional and perilesional inflammatory reaction and several clinicopathological features associated with worse prognosis, including clinical stage, tumour size, mitotic count, lymphovascular invasion and lymph node metastasis. Furthermore, tertiary lymphoid structures were significantly more frequent in tumours with an infiltrative growth and lymph node metastasis. According to our results, the inflammatory reaction present in different types of feline mammary lesions is associated with the development of more aggressive tumours.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fundação para a Ciência e a Tecnologia (FCT)
ID : 2022.09644.BD
Organisme : Fundação para a Ciência e a Tecnologia (FCT)
ID : UIDB/00772/2020
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
E. Manuali, C. Forte, G. Vichi, et al., “Tumours in European Shorthair Cats: A Retrospective Study of 680 Cases,” Journal of Feline Medicine and Surgery 22, no. 12 (2020): 1095–1102.
K. Pinello, I. Pires, A. F. Castro, et al., “Vet‐OncoNet: Developing a Network of Veterinary Oncology and Reporting a Pioneering Portuguese Experience,” Veterinary Science 9, no. 2 (2022): 72.
F. Giménez, S. Hecht, L. E. Craig, and A. M. Legendre, “Early Detection, Aggressive Therapy: Optimizing the Management of Feline Mammary Masses,” Journal of Feline Medicine and Surgery 12, no. 3 (2010): 214–224.
J. Morris, “Mammary Tumours in the Cat: Size Matters, So Early Intervention Saves Lives,” Journal of Feline Medicine and Surgery 15, no. 5 (2013): 391–400.
A. Gameiro, A. C. Urbano, and F. Ferreira, “Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma,” Veterinary Science 8, no. 8 (2021): 164.
G. Petrucci, J. Henriques, L. Lobo, et al., “Adjuvant Doxorubicin vs Metronomic Cyclophosphamide and Meloxicam vs Surgery Alone for Cats With Mammary Carcinomas: A Retrospective Study of 137 Cases,” Veterinary and Comparative Oncology 19, no. 4 (2020): 714–723.
G. Petrucci, J. Henriques, H. Gregório, et al., “Metastatic Feline Mammary Cancer: Prognostic Factors, Outcome and Comparison of Different Treatment Modalities – A Retrospective Multicentre Study,” Journal of Feline Medicine and Surgery 23, no. 6 (2021): 549–556.
F. R. Greten and S. I. Grivennikov, “Inflammation and Cancer: Triggers, Mechanisms and Consequences,” Immunity 51, no. 1 (2019): 27–41.
D. C. Hinshaw and L. A. Shevde, “The Tumor Microenvironment Innately Modulates Cancer Progression,” Cancer Research 79, no. 18 (2019): 4557–4566.
R. J. Seager, C. Hajal, F. Spill, R. D. Kamm, and M. H. Zaman, “Dynamic Interplay Between Tumour, Stroma and Immune System Can Drive or Prevent Tumour Progression,” Convergent Science Physical Oncology 3 (2017): 034002.
S. Shalapour and M. Karin, “Pas de Deux: Control of Anti‐Tumor Immunity by Cancer‐Associated Inflammation,” Immunity 51, no. 1 (2019): 15–26.
A. C. Degnim, R. D. Brahmbhatt, D. C. Radisky, et al., “Immune Cell Quantitation in Normal Breast Tissue Lobules With and Without Lobulitis,” Breast Cancer Research and Treatment 144, no. 3 (2014): 539–549.
A. C. Degnim, T. L. Hoskin, M. Arshad, et al., “Alterations in the Immune Cell Composition in Premalignant Breast Tissue That Precede Breast Cancer Development,” Clinical Cancer Research 23, no. 14 (2017): 3945–3952.
D. N. Danforth, “The Role of Chronic Inflammation in the Development of Breast Cancer,” Cancers 13 (2021): 3918.
G. Giambrone, S. Di Giorgio, C. Vullo, et al., “Does TLS Exist in Canine Mammary Gland Tumours? Preliminary Results in Simple Carcinomas,” Veterinary Sciences 9, no. 11 (2022): 628.
N. N. Zhang, F. J. Qu, H. Liu, et al., “Prognostic Impact of Tertiary Lymphoid Structures in Breast Cancer Prognosis: A Systematic Review and Meta‐Analysis,” Cancer Cell International 21, no. 1 (2021): 536.
C. Nascimento and F. Ferreira, “Tumor Microenvironment of Human Breast Cancer, and Feline Mammary Carcinoma as a Potential Study Model,” Biochimica et Biophysica Acta – Reviews on Cancer 1876, no. 1 (2021): 188587.
V. Zappulli, G. D. Zan, B. Cardazzo, L. Bargelloni, and M. Castagnaro, “Feline Mammary Tumours in Comparative Oncology,” Journal of Dairy Research 72, no. S1 (2005): 98–106.
E. Dagher, J. Abadie, D. Loussouarn, M. Campone, and F. Nguyen, “Feline Invasive Mammary Carcinomas: Prognostic Value of Histological Grading,” Veterinary Pathology 56, no. 5 (2019): 660–670.
E. Dagher, L. Simbault, J. Abadie, D. Loussouarn, M. Campone, and F. Nguyen, “Identification of an Immune‐Suppressed Subtype of Feline Triple‐Negative Basal‐Like Invasive Mammary Carcinomas, Spontaneous Models of Breast Cancer,” Tumour Biology 42, no. 1 (2020): 1010428319901052.
K. Weijer and A. A. Hart, “Prognostic Factors in Feline Mammary Carcinoma,” Journal of the National Cancer Institute 70, no. 4 (1983): 709–716.
C. Nascimento, A. Gameiro, J. Correia, J. Ferreira, and F. Ferreira, “The Landscape of Tumor‐Infiltrating Immune Cells in Feline Mammary Carcinoma: Pathological and Clinical Implications,” Cells 11, no. 16 (2022): 2578.
M. Zareinejad, F. Mehdipour, M. Roshan‐Zamir, Z. Faghih, and A. Ghaderi, “Dual Functions of T Lymphocytes in Breast Carcinoma: From Immune Protection to Orchestrating Tumor Progression and Metastasis,” Cancers 15, no. 19 (2023): 4771.
Y. Jiang, Y. Li, and B. Zhu, “T‐Cell Exhaustion in the Tumor Microenvironment,” Cell Death & Disease 6, no. 6 (2015): e1792.
M. Davoodzadeh Gholami, G. A. Kardar, Y. Saeedi, S. Heydari, J. Garssen, and R. Falak, “Exhaustion of T Lymphocytes in the Tumor Microenvironment: Significance and Effective Mechanisms,” Cellular Immunology 322 (2017): 1–14.
A. C. Urbano, C. Nascimento, M. Soares, J. Correia, and F. Ferreira, “Clinical Relevance of the Serum CTLA‐4 in Cats With Mammary Carcinoma,” Scientific Reports 10, no. 1 (2020): 3822.
C. Nascimento, A. C. Urbano, A. Gameiro, J. Ferreira, J. Correia, and F. Ferreira, “Serum PD‐1/PD‐L1 Levels, Tumor Expression and PD‐L1 Somatic Mutations in HER2‐Positive and Triple Negative Normal‐Like Feline Mammary Carcinoma Subtypes,” Cancers 12, no. 6 (2020): 1386.
A. Gameiro, C. Nascimento, J. Correia, and F. Ferreira, “VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes,” Cancers 13, no. 21 (2021): 5559.
S. Valente, C. Nascimento, A. Gameiro, J. Ferreira, J. Correia, and F. Ferreira, “TIM‐3 Is a Potential Immune Checkpoint Target in Cats With Mammary Carcinoma,” Cancers 15, no. 2 (2023): 384.
V. Zappulli, L. Peña, R. Rasotto, et al., “Classification of Feline Mammary Tumors,” in Mammary Tumors. Surgical Pathology of Tumors of Domestic Animals, vol. 2, ed. M. Kiupel (Gurnee: Davis‐Thompson DVM Foundation, 2019), 197–264.
C. W. Elston and I. O. Ellis, “Pathological Prognostic Factors in Breast Cancer. I. The Value of Histological Grade in Breast Cancer: Experience From a Large Study With Long‐Term Follow‐Up,” Histopathology 19, no. 5 (1991): 403–410.
D. J. Meuten, C. A. Bertram, F. M. Moore, et al., “Mitotic Count Guideline, Version 1.0. Veterinary Cancer Guidelines and Protocols” 2021, https://vetcancerprotocols.org.
F. M. Moore, L. Craig, T. A. Donovan, et al., “Lymphovascular Invasion Guideline, Version 2.0. Veterinary Cancer Guidelines and Protocols” 2024, https://vetcancerprotocols.org.
C. J. McNeill, K. U. Sorenmo, F. S. Shofer, et al., “Evaluation of Adjuvant Doxorubicin‐Based Chemotherapy for the Treatment of Feline Mammary Carcinoma,” Journal of Veterinary Internal Medicine 23, no. 1 (2009): 123–129.
F. Chocteau, M. M. Boulay, F. Besnard, G. Valeau, D. Loussouarn, and F. Nguyen, “Proposal for a Histological Staging System of Mammary Carcinomas in Dogs and Cats. Part 2: Feline Mammary Carcinomas,” Frontiers in Veterinary Science 6 (2019): 387.
A. Estrela‐Lima, M. S. S. Araújo, J. M. Costa‐Neto, et al., “Immunophenotypic Features of Tumor Infiltrating Lymphocytes From Mammary Carcinomas in Female Dogs Associated With Prognostic Factors and Survival Rates,” BMC Cancer 10 (2010): 256.
R. Salgado, C. Denkert, S. Demaria, et al., “The Evaluation of Tumor‐Infiltrating Lymphocytes (TILs) in Breast Cancer: Recommendations by an International TILs Working Group 2014,” Annals of Oncology 26, no. 2 (2015): 259–271.
M. Sofopoulos, S. P. Fortis, C. K. Vaxevanis, et al., “The Prognostic Significance of Peritumoral Tertiary Lymphoid Structures in Breast Cancer,” Cancer Immunology, Immunotherapy: CII 68, no. 11 (2019): 1733–1745.
T. A. De Souza, C. B. De Campos, A. De Biasi Bassani Gonçalves, et al., “Relationship Between the Inflammatory Tumor Microenvironment and Different Histologic Types of Canine Mammary Tumors,” Research in Veterinary Science 119 (2018): 209–214.
F. Seixas, M. A. Pires, and C. A. Lopes, “Complex Carcinomas of the Mammary Gland in Cats: Pathological and Immunohistochemical Features,” Veterinary Journal 176, no. 2 (2008): 210–215.
L. V. Muscatello, G. Avallone, B. Brunetti, B. Bacci, M. P. Foschini, and G. Sarli, “Standardized Approach for Evaluating Tumor Infiltrating Lymphocytes in Canine Mammary Carcinoma: Spatial Distribution and Score as Relevant Features of Tumor Malignancy,” Veterinary Journal 283–284 (2022): 105833.
A. Tiwari, T. Oravecz, L. A. Dillon, et al., “Towards a Consensus Definition of Immune Exclusion in Cancer,” Frontiers in Immunology 14 (2023): 10848.
E. Dagher, J. Abadie, D. Loussouarn, D. Fanuel, M. Campone, and F. Nguyen, “Bcl‐2 Expression and Prognostic Significance in Feline Invasive Mammary Carcinomas: A Retrospective Observational Study,” BMC Veterinary Research 15, no. 1 (2019): 25.
H. J. Lee, I. A. Park, I. H. Song, et al., “Tertiary Lymphoid Structures: Prognostic Significance and Relationship With Tumour‐Infiltrating Lymphocytes in Triple‐Negative Breast Cancer,” Journal of Clinical Pathology 69, no. 5 (2015): 422–430.
S. L. Figenschau, S. Fismen, K. A. Fenton, C. Fenton, and E. S. Mortensen, “Tertiary Lymphoid Structures Are Associated With Higher Tumor Grade in Primary Operable Breast Cancer Patients,” BMC Cancer 15, no. 1 (2015): 101.
E. F. Need, V. Atashgaran, W. V. Ingman, and P. Dasari, “Hormonal Regulation of the Immune Microenvironment in the Mammary Gland,” Journal of Mammary Gland Biology and Neoplasia 19, no. 2 (2014): 229–239.
H. Tower, G. Dall, A. Davey, et al., “Estrogen‐Induced Immune Changes Within the Normal Mammary Gland,” Scientific Reports 12, no. 1 (2022): 18986.